CLK2-SOX3 combination promotes choroidal neovascularization by SGLT1 inducing endothelial cell metabolic...

Area of Science:

• Ophthalmology
• Molecular Biology
• Cell Biology

Background:

• Choroidal neovascularization (CNV) is a primary cause of vision loss.
• Endothelial cell metabolic reprogramming is crucial for pathological neovascularization.
• The regulation of endothelial cell metabolism in CNV remains poorly understood.

Purpose of the Study:

• To elucidate the regulatory mechanisms of endothelial cell metabolic reprogramming in CNV.
• To identify key molecular players involved in CNV pathogenesis.

Main Methods:

• Construction of laser-induced CNV mouse models and hypoxia-induced mouse brain microvascular endothelial cell (BMEC) models.
• Utilized siRNA transfection and metabolomics analysis to identify key regulators.
• Investigated protein-protein interactions and promoter targeting using molecular biology techniques.

Main Results:

• Identified Sodium-Dependent Glucose Transporter 1 (SGLT1) as a regulator of endothelial cell metabolic reprogramming in CNV.
• Demonstrated that SRY-box transcription factor 3 (SOX3) targets specific sequences in the sglt1 promoter.
• Revealed that CDC-like kinase 2 (CLK2) binding to SOX3 at Ser97 induces SOX3 function.

Conclusions:

• The CLK2-SOX3 complex promotes CNV by targeting SGLT1, leading to endothelial cell metabolic reprogramming.
• This pathway represents a novel mechanism underlying pathological neovascularization in the eye.
• Findings provide potential therapeutic targets for treating CNV.